China HEAD: a large community study on healthy aging and dementia
Official title: China HEalthy Aging and Dementia Study (HEAD)
Run by Fudan University · NCT07912710 · Data updated 2026-11-12
This study tests whether collecting health, imaging, and biospecimen data from adults in China can help predict who will develop Alzheimer’s disease and related dementias.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 20000 (estimated) |
| Sponsor | Fudan University Academic / other |
| Locations | 30 sites (Beijing and 29 other locations) |
| Status | Recruiting |
| Started | August 1, 2022 |
| Main results expected | August 1, 2072 |
| Study ends | August 1, 2072 |
| Registry record updated | November 3, 2026 |
| Trial ID | NCT07912710 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 50–79 living in China who can participate in long-term follow-up and consent to biospecimen donation and data collection.
✕Probably not a fit
Individuals without risk factors or those unable to participate in long-term follow-up may derive limited or no direct benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The China HEAD study is a large, prospective, community-based cohort enrolling about 20,000 adults aged 50–79 across multiple regions in China. It collects detailed clinical data, cognitive assessments, physical measurements, biospecimens, and, when feasible, electrophysiology and imaging data to explore early signs of cognitive decline and ADRD. Participants are followed annually for up to 50 years to observe progression from normal cognition to MCI and dementia. The study has a biobank and multi-omics component to support future research and potential intervention studies. Ethical approval was obtained, and informed consent is collected at baseline.
Why it matters
Potential benefit: If successful, the study could enable earlier prediction and diagnosis of ADRD in Chinese populations, guiding prevention and intervention efforts.
How similar studies have gone: Previous international cohort studies have shown value in similar multi-omics and imaging approaches for predicting cognitive decline, though population-specific validation in China is central here.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: China HEAD Community Cohort: 1. Resident in a Chinese community. 2. Aged 50-79 years. 3. Have adequate vision and hearing (with glasses or hearing aids if necessary), and be able to walk, communicate, and complete study-related assessments (including questionnaires, physical examinations, neuropsychological assessments, and biospecimen collection) independently or with assistance. 4. Willing to provide written informed consent for baseline assessments, follow-up, biospecimen donation, and data collection. China HEAD Familial Sub-cohort: 1. Resident in a Chinese community. 2. Aged 18 years or older. 3. Have a family history of Alzheimer's disease (AD) involving at least two first-degree relatives across at least two consecutive generations, with AD diagnoses previously established at tertiary hospitals and verified through medical history. 4. Meet the 2011 National Institute on Aging-Alzheimer's Association (NIA-AA) diagnostic criteria for AD. 5. Have adequate vision and hearing (with glasses or hearing aids if necessary), and be able to walk, communicate, and complete study-related assessments (including questionnaires, physical examinations, neuropsychological assessments, and biospecimen collection) independently or with assistance. 6. Willing to provide written informed consent for baseline assessments, follow-up, biospecimen donation, and data collection. Exclusion Criteria: The following exclusion criteria apply to participants in the HEAD study: 1. Refusal to provide written informed consent. 2. Refusal to participate in questionnaires or other data collection procedures. 3. Refusal to provide blood or other biological samples. 4. Self-reported stroke events (e.g., cerebral hemorrhage or cerebral infarction) within the past six months. 5. Self-reported diseases potentially impairing cognition, including congenital intellectual disability, intracranial tumors, epilepsy, Parkinson's disease, or severe psychiatric disorders such as schizophrenia requiring medication. 6. Self-reported major organ failure (e.g., liver or kidney failure), malignancy, or other conditions associated with a shortened life expectancy that prevent completion of follow-up assessments. Additional exclusion criteria for participants undergoing magnetic resonance imaging (MRI): 1\. Inability to tolerate MRI examinations or contraindications to MRI, including claustrophobia; MRI-incompatible implanted pacemakers, aneurysm clips, artificial heart valves, cochlear implants, or other metallic implants; or other clinical conditions or examination findings that investigators consider potentially harmful during MRI.
Where it's running
-
Beijing Normal University
Beijing, China Recruiting -
Beijing Tiantan Hospital, Capital Medical University
Beijing, China Recruiting -
Beijing University of Posts and Telecommunications
Beijing, China Recruiting -
Chinese PLA General Hospital
Beijing, China Recruiting -
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences
Beijing, China Recruiting -
Peking Union Medical College Hospital
Beijing, China Recruiting
Show 24 more locations
-
Peking University
Beijing, China Recruiting -
Xuanwu Hospital, Capital Medical University
Beijing, China Recruiting -
Jilin University
Changchun, China Recruiting -
Sichuan University
Chengdu, China Recruiting -
Army Medical University, China
Chongqing, China Recruiting -
Fujian Medical University
Fuzhou, China Recruiting -
Southern Medical University
Guangzhou, China Recruiting -
Sun Yat-sen University
Guangzhou, China Recruiting -
The First Affiliated Hospital of University of Science and Technology of China
Hefei, China Recruiting -
Shandong First Medical University
Jinan, China Recruiting -
Southeast University, China
Nanjing, China Recruiting -
Qingdao University
Qingdao, China Recruiting -
Fudan University
Shanghai, China Recruiting -
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, China Recruiting -
Shanghai University
Shanghai, China Recruiting -
Tongji University
Shanghai, China Recruiting -
Shenzhen Bay Laboratory
Shenzhen, China Recruiting -
Shenzhen University
Shenzhen, China Recruiting -
Fudan University Taizhou Institute of Health Sciences
Taizhou, China Recruiting -
Tianjin Medical University
Tianjin, China Recruiting -
Wuhan University of Science and Technology
Wuhan, China Recruiting -
The First Affiliated Hospital of Xiamen University
Xiamen, China Recruiting -
Qinghai Provincial People's Hospital
Xining, China Recruiting -
Zhoukou Central Hospital
Zhoukou, China Recruiting
Study contacts
- Study coordinator: Jin-Tai Yu, MD, PhD
- Email: jintai_yu@fudan.edu.cn
- Phone: +86 18678999982
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns
This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.
-
Cognition and Aging in China
This study is trying to gather information from people in China with different types of dementia and mild cognitive impairment to better understand the condition and improve how it's diagnosed and treated.
-
Comprehensive assessment of neurodegeneration and dementia
This project will collect brain scans, cognitive tests, and biological samples over time to see how dementia and related conditions progress in adults aged 50–90, including people with Parkinson's and people without cognitive problems.
-
Aging Brain Health Initiative in Fujian
This observational study will follow about 3,000 older adults in Fujian to see how Alzheimer's-related changes develop and to test new digital tests, biomarkers, and imaging tools for early diagnosis.
-
Photobiomodulation therapy for mild cognitive impairment and mild Alzheimer's disease
This trial tests whether daily transcranial near-infrared light therapy, versus a sham device, can improve cognitive function in adults with mild cognitive impairment or mild Alzheimer's disease.
-
Gut and Oral Microbiome and Cognitive Health in Aging
This study tests whether differences in gut and mouth bacteria are linked to cognitive health in adults across ages and cognitive status.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.